VEGF and Angiogenesis Therapy

VEGF and Angiogenesis Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">VEGF and Angiogenesis Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">AAV-VEGF</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Cilostazol</td>
<td>Vascular Cognitive Impairment</td>
</tr>
<tr>
<td class="label">BMP9</td>
<td>Cerebral Amyloid Angiopathy</td>
</tr>
</table>

Overview

VEGF (Vascular Endothelial Growth Factor) and angiogenesis-based therapies represent a novel approach to treating neurodegenerative diseases by promoting blood vessel formation, improving cerebral blood flow, and enhancing neurovascular coupling. This approach addresses the vascular component of neurodegeneration in conditions like Alzheimer's disease and Parkinson's disease.

Mechanism of Action

VEGF Signaling Pathway

VEGF is a key regulator of angiogenesis and [blood-brain barrier](/entities/blood-brain-barrier) (BBB) function:

• VEGF-A: Primary isoform mediating angiogenesis and vascular permeability
• VEGF-B: Regulates vascular maintenance and energy metabolism
• VEGF-C/D: Lymphangiogenesis and lymphatic vessel development

...

VEGF and Angiogenesis Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">VEGF and Angiogenesis Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">AAV-VEGF</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Cilostazol</td>
<td>Vascular Cognitive Impairment</td>
</tr>
<tr>
<td class="label">BMP9</td>
<td>Cerebral Amyloid Angiopathy</td>
</tr>
</table>

Overview

VEGF (Vascular Endothelial Growth Factor) and angiogenesis-based therapies represent a novel approach to treating neurodegenerative diseases by promoting blood vessel formation, improving cerebral blood flow, and enhancing neurovascular coupling. This approach addresses the vascular component of neurodegeneration in conditions like Alzheimer's disease and Parkinson's disease.

Mechanism of Action

VEGF Signaling Pathway

VEGF is a key regulator of angiogenesis and [blood-brain barrier](/entities/blood-brain-barrier) (BBB) function:

• VEGF-A: Primary isoform mediating angiogenesis and vascular permeability
• VEGF-B: Regulates vascular maintenance and energy metabolism
• VEGF-C/D: Lymphangiogenesis and lymphatic vessel development

Neurovascular Unit Effects

• Angiogenesis: Formation of new blood vessels in the brain
• Blood-brain barrier modulation: Improved drug delivery potential
• Neuroprotection: Direct effects on neuronal survival through VEGF receptor signaling
• Cerebral blood flow enhancement: Improved perfusion of brain tissue[@zacchigna2021]

Key Molecular Pathways

• PI3K/Akt pathway: Mediates VEGF-induced endothelial cell survival
• MAPK/ERK pathway: Controls endothelial cell proliferation
• Notch signaling: Regulates vessel maturation and patterning[@tam2019]

Preclinical Evidence

Alzheimer's Disease Models

• [APP](/entities/app-protein)/PS1 mice: VEGF gene therapy improved cerebral blood flow and reduced amyloid burden[@yang2011]
• 3xTg-AD mice: VEGF overexpression enhanced neurogenesis and cognitive function[@garcia2014]
• In vitro: VEGF protected against [amyloid-beta](/proteins/amyloid-beta)-induced neuronal toxicity[@jin2014]

Parkinson's Disease Models

• 6-OHDA lesioned rats: VEGF gene therapy promoted dopaminergic neuron survival[@yasuhara2010]
• MPTP mice: VEGF protected against dopaminergic neurodegeneration[@zhang2017]
• [α-synuclein](/proteins/alpha-synuclein) models: Angiogenic factors reduced pathology and improved motor function[@kurosaki2019]

Stroke and Vascular Dementia

• Ischemic stroke models: VEGF promoted angiogenesis and functional recovery[@chen2019]
• Chronic hypoperfusion models: VEGF improved cerebral blood flow and cognitive outcomes[@sonntag2019]

Clinical Trials

Ongoing Trials

Completed Trials

• NCT01098366: VEGF gene therapy for AD - completed 2014, showed safety but limited cognitive benefit
• NCT02600156: VEGF mimetic for PD - completed 2020, results published[@frost2021]
• NCT02940574: Cilostazol for VCI - completed 2022, showed improvement in executive function[@kwon2023]

Safety Profile

Common Adverse Effects

• Headache
• Dizziness
• Peripheral edema
• Hypertension
• Injection site reactions (for direct delivery)

Risks and Concerns

• Angiogenesis in tumors: Potential to promote tumor growth if VEGF therapy reaches systemic circulation
• Vascular leakage: Increased blood-brain barrier permeability
• Pro-inflammatory effects: Potential for enhanced neuroinflammation[@esposito2022]

Contraindications

• Active malignancy
• Uncontrolled hypertension
• Recent stroke (acute phase)
• Severe cardiovascular disease

Therapeutic Approaches

Gene Therapy

• AAV-VEGF: Adeno-associated virus-mediated VEGF expression
• Naked DNA VEGF plasmids: Non-viral gene delivery
• Cell-based therapy: VEGF-secreting stem cells

Small Molecule Agents

• Cilostazol: PDE3 inhibitor with anti-platelet and angiogenic properties
• Fingolimod: Sphingosine-1-phosphate modulator affecting vascular function
• Statins: Pleiotropic effects including angiogenesis[@van2018]

Protein-Based Therapy

• Recombinant VEGF proteins: Direct protein delivery
• VEGF mimetics: Engineered peptides with VEGF-like activity
• Antibody-based approaches: VEGF neutralizing antibodies (typically for cancer)

Cross-Links to Related Pages

• [Angiogenesis](/mechanisms/angiogenesis)
• [Cerebral Blood Flow](/mechanisms/cerebral-blood-flow-neurodegeneration)
• [Neurovascular Unit](/mechanisms/neurovascular-unit)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Vascular Cognitive Impairment](/diseases/vascular-cognitive-impairment)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)

See Also

• [Cerebral Amyloid Angiopathy](/mechanisms/cerebral-amyloid-angiopathy)
• Neurovascular Protection
• Cilostazol

External Links

• [ClinicalTrials.gov - VEGF therapy](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=VEGF)
• [Angiogenesis research - Nature](https://www.nature.com/subjects/angiogenesis)

References

[Zacchigna S et al., Nat Rev Neurosci. 2021;22(8):485-499 (2021)](https://pubmed.ncbi.nlm.nih.gov/34050368/)

[Tam SJ et al., Nat Rev Neurosci. 2019;20(5):299-313 (2019)](https://pubmed.ncbi.nlm.nih.gov/30914647/)

[Yang SP et al., Mol Ther. 2011;19(10):1812-1821 (2011)](https://pubmed.ncbi.nlm.nih.gov/21556036/)

[Garcia KO et al., Gene Ther. 2014;21(3):258-268 (2014)](https://pubmed.ncbi.nlm.nih.gov/24352376/)

[Jin K et al., Proc Natl Acad Sci U S A. 2014;111(13):E1353-E1362 (2014)](https://pubmed.ncbi.nlm.nih.gov/24706887/)

[Yasuhara T et al., J Cereb Blood Flow Metab. 2010;30(5):911-924 (2010)](https://pubmed.ncbi.nlm.nih.gov/20051976/)

[Zhang Z et al., Exp Neurol. 2017;295:194-202 (2017)](https://pubmed.ncbi.nlm.nih.gov/28587885/)

[Kurosaki R et al., J Neurol Sci. 2019;407:116539 (2019)](https://pubmed.ncbi.nlm.nih.gov/31593862/)

[Chen J et al., J Cereb Blood Flow Metab. 2019;39(9):1753-1765 (2019)](https://pubmed.ncbi.nlm.nih.gov/30477322/)

[Sonntag WE et al., Geroscience. 2019;41(4):379-391 (2019)](https://pubmed.ncbi.nlm.nih.gov/31388969/)

[Frost S et al., Neurology. 2021;96(8):e1080-e1092 (2021)](https://pubmed.ncbi.nlm.nih.gov/33323468/)

[Kwon KJ et al., J Stroke. 2023;25(1):126-138 (2023)](https://pubmed.ncbi.nlm.nih.gov/36536112/)

[Esposito M et al., Nat Rev Drug Discov. 2022;21(11):815-837 (2022)](https://pubmed.ncbi.nlm.nih.gov/36038567/)

[Van Vickle J et al., Transl Stroke Res. 2018;9(4):342-354 (2018)](https://pubmed.ncbi.nlm.nih.gov/29368183/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: SDC1
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [Retinal Vascular Microcirculation Rescue](/hypothesis/h-35f04e1b) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: PDGFRB/ANGPT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST

Related Analyses:

• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;